Showing results (61-70 of 157) with videos related to
Sort By:
Pageof 16
Plos One|September 16, 2014
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesotheliomaRajani Kanteti, Immanuel Dhanasingh, Ichiro Kawada, et al.Cancer|June 11, 2008
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesotheliomaDavid M Jackman, Hedy L Kindler, Beow Y Yeap, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan, Nicholas J Vogelzang, Everett E Vokes, et al.Cancer|June 30, 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)Andrew S Roberts, Michael J Campa, Elizabeth B Gottlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesotheliomaGiorgio V Scagliotti, Dong-M Shin, Hedy L Kindler, et al.Cancer|January 16, 2019
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignanciesManish R Sharma, Smita S Joshi, Theodore G Karrison, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke, Margaret A Tempero, Donna Niedzwiecki, et al.Investigational New Drugs|June 25, 2010
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinomaManish A Shah, Derek G Power, Hedy L Kindler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesotheliomaRaffit Hassan, Hedy L Kindler, Thierry Jahan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitorIan McCaffery, Yanyan Tudor, Hongjie Deng, et al.Pageof 16